» Articles » PMID: 25924916

Mutations Upstream of FabI in Triclosan Resistant Staphylococcus Aureus Strains Are Associated with Elevated FabI Gene Expression

Overview
Journal BMC Genomics
Publisher Biomed Central
Specialty Genetics
Date 2015 May 1
PMID 25924916
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The enoyl-acyl carrier protein (ACP) reductase enzyme (FabI) is the target for a series of antimicrobial agents including novel compounds in clinical trial and the biocide triclosan. Mutations in fabI and heterodiploidy for fabI have been shown to confer resistance in S. aureus strains in a previous study. Here we further determined the fabI upstream sequence of a selection of these strains and the gene expression levels in strains with promoter region mutations.

Results: Mutations in the fabI promoter were found in 18% of triclosan resistant clinical isolates, regardless the previously identified molecular mechanism conferring resistance. Although not significant, a higher rate of promoter mutations were found in strains without previously described mechanisms of resistance. Some of the mutations identified in the clinical isolates were also detected in a series of laboratory mutants. Microarray analysis of selected laboratory mutants with fabI promoter region mutations, grown in the absence of triclosan, revealed increased fabI expression in three out of four tested strains. In two of these strains, only few genes other than fabI were upregulated. Consistently with these data, whole genome sequencing of in vitro selected mutants identified only few mutations except the upstream and coding regions of fabI, with the promoter mutation as the most probable cause of fabI overexpression. Importantly the gene expression profiling of clinical isolates containing similar mutations in the fabI promoter also showed, when compared to unrelated non-mutated isolates, a significant up-regulation of fabI.

Conclusions: In conclusion, we have demonstrated the presence of C34T, T109G, and A101C mutations in the fabI promoter region of strains with fabI up-regulation, both in clinical isolates and/or laboratory mutants. These data provide further observations linking mutations upstream fabI with up-regulated expression of the fabI gene.

Citing Articles

The mobilome landscape of biocide-resistance in Brazilian ESKAPE isolates.

da Rosa E, Kremer F Braz J Microbiol. 2024; 55(4):3603-3616.

PMID: 39028534 PMC: 11712051. DOI: 10.1007/s42770-024-01450-7.


Evolution of triclosan resistance modulates bacterial permissiveness to multidrug resistance plasmids and phages.

Yang Q, Ma X, Li M, Zhao M, Zeng L, He M Nat Commun. 2024; 15(1):3654.

PMID: 38688912 PMC: 11061290. DOI: 10.1038/s41467-024-48006-9.


Machine learning and phylogenetic analysis allow for predicting antibiotic resistance in M. tuberculosis.

Yurtseven A, Buyanova S, Agrawal A, Bochkareva O, Kalinina O BMC Microbiol. 2023; 23(1):404.

PMID: 38124060 PMC: 10731705. DOI: 10.1186/s12866-023-03147-7.


Experimental evolution in morbidostat reveals converging genomic trajectories on the path to triclosan resistance.

Leyn S, Zlamal J, Kurnasov O, Li X, Elane M, Myjak L Microb Genom. 2021; 7(5).

PMID: 33945454 PMC: 8209735. DOI: 10.1099/mgen.0.000553.


A platform for detecting cross-resistance in antibacterial drug discovery.

Galarion L, Mohamad M, Alzeyadi Z, Randall C, ONeill A J Antimicrob Chemother. 2021; 76(6):1467-1471.

PMID: 33755133 PMC: 8843079. DOI: 10.1093/jac/dkab063.


References
1.
Tkachenko O, Shepard J, Aris V, Joy A, Bello A, Londono I . A triclosan-ciprofloxacin cross-resistant mutant strain of Staphylococcus aureus displays an alteration in the expression of several cell membrane structural and functional genes. Res Microbiol. 2007; 158(8-9):651-8. DOI: 10.1016/j.resmic.2007.09.003. View

2.
Smith K, Gemmell C, Hunter I . The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates. J Antimicrob Chemother. 2007; 61(1):78-84. DOI: 10.1093/jac/dkm395. View

3.
Jang H, Chang M, Toghrol F, Bentley W . Microarray analysis of toxicogenomic effects of triclosan on Staphylococcus aureus. Appl Microbiol Biotechnol. 2008; 78(4):695-707. DOI: 10.1007/s00253-008-1349-x. View

4.
Correa J, De Paulis A, Predari S, Sordelli D, Jeric P . First report of qacG, qacH and qacJ genes in Staphylococcus haemolyticus human clinical isolates. J Antimicrob Chemother. 2008; 62(5):956-60. DOI: 10.1093/jac/dkn327. View

5.
Karlowsky J, Kaplan N, Hafkin B, Hoban D, Zhanel G . AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother. 2009; 53(8):3544-8. PMC: 2715641. DOI: 10.1128/AAC.00400-09. View